Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion (3)

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.

The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion. Blueprint brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition ...